Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘CDK9’

Who, and importantly, what is in the spotlight at AACR21?

In our third Preview of the AACR21 annual meeting series, it’s time to highlight some early or promising new categories, some of which involve some elegant or cool science concepts.

Here we selected our Top 8 emerging areas of innovative research in targeted therapies.  The immunotherapy developments will be covered separately.

So what ideas should you be looking over your shoulders at and which ones might make you shudder in horror?

After all, oncology R&D is very much a game of Yin and Yang – for every great new idea that comes along there’s always something in the category which makes you go, “Huh?!”

Hurry along and see what’s in the spotlight this year…

To learn more about the hot topics at AACR21 and get a heads up on our oncology commentary and insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

In the last post from SABCS, we looked at what’s new on the translational front with the MYC oncogene in terms of breast cancer.

This time around we turn our attention to other targets and subsets of interest, which don’t involve immunotherapy – more on the latter in a separate article.

Today’s featured image is inspired by my dear friend Jody Schoger and Lisa Adams, who inspired us to find a little beauty in the world each day, no matter how hard it might seem.  2015 was very bad year for losing wonderful BioTwitter chums in the breast cancer community – they may be gone, but never forgotten 🙁

In particular, we highlight new developments in four key areas of interest, with some intriguing observations to discuss…

To learn more from our oncology analysis and get a heads up on the latest insights and commentary pertaining to the SABCS meeting, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Finding pathways to success in breast cancer

The last week brough a huge tsunami of data across varied topics ranging from hematologic malignancies (ASH), breast cancer (SABCS) and immunotherapies (ESMO IO) – we’re still digging our way out of it all!

There’s plenty of detailed analyses yet to come from all of these meetings, including some KOL interviews and thought provoking pieces to consider as well.

Here we look at some translational findings from academic researchers as well as companies involved in clinical trials in breast cancer. Yes, it’s time for some post SABCS reviews on a series of different topics…

To learn more from our oncology analysis and get a heads up on the latest insights and commentary pertaining to the SABCS meeting, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

 

A look at upregulated targets outside of the BCR signalling pathway and what small molecules are looking promising

In our final preview of ASH 2020 exploring key abstracts and what to watch out for this weekend, we offer the second half of our discussion around small molecules in early stage development.

There’s always a roller coaster ride in any early stage drug development and small molecule inhibitors are no different from antibodies, bispecifics, or even immunotherapies in this respect.

There are certainly some unexpected and surprising overlaps discussed and uncovered here plus also some novel combination approaches either being considered or which may potentially need to be considered in the future.

So what’s in store this time around?

To learn more from our oncology analysis and get a heads up on the latest insights and commentary pertaining to the ASH meeting — including our final Preview ahead of the meeting this weekend, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

It’s all too easy to focus on the here, the now, and what’s hot in the moment, but let’s also remember that while immunotherapy and KRAS might be the hottest topics out there in oncology R&D at the moment, we still need to induce durable and lasting tumour cell killing or the cancer won’t be penned in.

Resistance mechanisms or immune escape will induce relapse, disease recurrence, and off we go again with tumour proliferation, sometimes at a more aggressive rate than before.

Back in the 1970s and earlier all we really had was a bunch of rather nasty and ineffective chemotherapies, often given in sequence, although improvements in dosing, scheduling, and also experimenting with different combinations eventually helped a great deal.

What if we were to look at modern methods of inducing cell death without the nihilistic side effects of old?

After a few false starts and quite a lot of agents condemned to dog drug heaven, we saw the emergence of the CDK4/6 inhibitors in HR+ breast cancer.  Since then a number of other targets have started showing up, not just as small molecules but also in quite different modalities.

Is this truly going to be a new revolution to think about or yet another raft of promising agents consigned to the dustbin of screening libraries? The good news is there are some hopeful signs finally peeping out…

To learn more from our oncology analysis and get a heads up on the latest insights and commentary, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

If you had told me several weeks ago that we would write over 28 posts on #AACR16 and become very interested in mouse models, then most likely I would have laughed out loud and told you not to be so ridiculous!  Here we are with the 29th one and, another, on the bromododomain landscape yet to go.  Such was the vast richness of data and concepts being discussed or presented in New Orleans for those who chose to look.

Today, I want to start the segue from AACR to ASCO coverage.

Nawlins MGRAS FIOne way to do that is through the second part of the Gems from the Post Hall series. This latest one looks at a range of intriguing new targeted therapies and novel targets that are emerging, including a pharma company with a particularly interesting early pipeline.

Several pharma companies presented interesting data on their very early compounds currently in development, plus I noticed a trend for a new class of targeted therapies to emerge, MNK inhibitors, which we will also discuss.

Companies mentioned: Bayer, Orion Pharma, Lilly, Novartis, Pfizer, Agios.

Targets mentioned: PI3K, CDK, Akt, TWEAK, FGFR, BUB1, IDH1, SMYD2, MNK

Subscribers can log-in below of you can purchase a subscription.

This content is restricted to subscribers

Free Email Updates
Subscribe to new post alerts, offers, and additional content!
We respect your privacy and do not sell emails. Unsubscribe at any time.
error: Content is protected !!